Icariin stimulates the osteogenic differentiation of rat bone marrow stromal cells via activating the PI3K-AKT-eNOS-NO-cGMP-PKG

Bone

Volumn 66, Issue , 2014, Pages 189-198

  Zhai, Yuan Kun ^a   Guo, Xiao Yu ^a   Ge, Bao Feng ^a   Zhen, Ping ^a   Ma, Xiao Ni ^a   Zhou, Jian ^a   Ma, Hui Ping ^a   Xian, Cory J ^b   Chen, Ke Ming ^a  

^a LANZHOU GENERAL HOSPITAL   (China)

^b UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

Author keywords

Bone marrow stromal cells; Icariin; Nitric oxide; Osteogenic differentiation; Signal transduction

Indexed keywords

1H 1,2,4 OXADIAZOLO[4,3 A]QUINOXALIN 1 ONE; 2 MORPHOLINO 8 PHENYLCHROMONE; ALKALINE PHOSPHATASE; CYCLIC GMP; CYCLIC GMP DEPENDENT PROTEIN KINASE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GUANYLATE CYCLASE; ICARIIN; INDUCIBLE NITRIC OXIDE SYNTHASE; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; OSTEOCALCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHODIESTERASE V; PROTEIN KINASE B; SOLUBLE GUANYLATE CYCLASE; UNCLASSIFIED DRUG; 2-(4-MORPHOLINYL)-8-PHENYL-4H-1-BENZOPYRAN-4-ONE; CHROMONE DERIVATIVE; ENZYME INHIBITOR; FLAVONOID; MORPHOLINE DERIVATIVE;

ADULT; ANIMAL CELL; ARTICLE; BONE DEVELOPMENT; BONE MARROW CELL; CELL DIFFERENTIATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; OSTEOBLAST; PROTEIN EXPRESSION; RAT; SIGNAL TRANSDUCTION; STROMA CELL; ANIMAL; CYTOLOGY; DRUG EFFECTS; ENZYME ACTIVATION; ENZYMOLOGY; MESENCHYMAL STROMA CELL; METABOLISM; PHENOTYPE; PHOSPHORYLATION; WISTAR RAT; BIOSYNTHESIS; BONE MARROW STROMA CELL; CALCIUM METABOLISM; CELL STIMULATION; COMBINATION CHEMOTHERAPY; DOSE RESPONSE;

ALKALINE PHOSPHATASE; ANIMALS; CELL DIFFERENTIATION; CHROMONES; CYCLIC GMP; CYCLIC GMP-DEPENDENT PROTEIN KINASES; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 5; ENZYME ACTIVATION; ENZYME INHIBITORS; FLAVONOIDS; MALE; MESENCHYMAL STROMAL CELLS; MORPHOLINES; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE III; OSTEOCALCIN; OSTEOGENESIS; PHENOTYPE; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RATS, WISTAR; SIGNAL TRANSDUCTION;

EID: 84903639742     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2014.06.016     Document Type: Article

References (59)

1. Rossouw J.E., Anderson G.L., Prentice R.J., LaCroix A.Z., Kooperberg C., Stefanick M.L., et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal woman: principle results from the Woman's Health Initiative randomized controlled trial. JAMA 2002, 288:321-333.
2. Russell R.G.G. Bisphosphonates: mode of action and pharmacology. Pediatrics 2007, 119:S150-S162.
3. Drake M.T., Clarke B.L., Khosla S. Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc 2008, 83:1032-1045.
4. Demontiero O., Vidal C., Duque G. Aging and bone loss: new insights for the clinician. Ther Adv Musculoskelet Dis 2012, 4:61-76.
5. Borrelli F., Ernst E. Alternative and complementary therapies for the menopause. Maturitas 2010, 66:333-343.
6. Peng S., Zhang G., He Y., Wang X., Leung P., Leung K., et al. Epimedium-derived flavonoids promote osteoblastogenesis and suppress adipogenesis in bone marrow stromal cells while exerting an anabolic effect on osteoporotic bone. Bone 2009, 45:534-544.
7. Xu Y.X., Xu B., Wu C.L., Wu Y., Tong P.J., Xiao L.W. Dynamic expression of DKK1 protein in the process whereby Epimedium-derived flavonoids up-regulate osteogenic and down-regulate adipogenic differentiation of bone marrow stromal cells in ovariectomized rats. Orthop Surg 2011, 3:119-126.
8. Zhang G., Qin L., Shi Y. Epimedium-derived phytoestrogen flavonoids exert beneficial effect on preventing bone loss in late postmenopausal women: a 24-month randomized, double-blind and placebo-controlled trial. J Bone Miner Res 2007, 22:1072-1079.
9. Shen P., Wong S.P., Li J., Yong E.L. Simple and sensitive liquid chromatography-tandem mass spectrometry assay for simultaneous measurement of five Epimedium prenylflavonoids in rat sera. J Chromatogr B Analyt Technol Biomed Life Sci 2009, 877:71-78.
10. Ye H.Y., Lou Y.J. Estrogenic effects of two derivatives of icariin on human breast cancer MCF-7 cells. Phytomedicine 2005, 12:735-741.
11. Chen K.M., Ge B.F., Ma H.P., Liu X.Y., Bai M.H., Wang Y. Icariin, a flavonoid from the herb Epimedium enhances the osteogenic differentiation of rat primary bone marrow stromal cells. Pharmazie 2005, 60:939-942.
12. Chen K.M., Ge B.F., Liu X.Y., Ma H.P., Lv M.B., Bai M.H. Icariin inhibits the osteoclast formation induced by RANKL and macrophage-colony stimulating factor in mouse bone marrow culture. Pharmazie 2007, 62:388-391.
13. Huang J., Yuan L., Wang X., Zhang T.L., Wang K. Icaritin and its glycosides enhance osteoblastic, but suppress osteoclastic, differentiation and activity in vitro. Life Sci 2007, 81:832-840.
14. Mok S.K., Chen W.F., Lai W.P., Leung P.C., Wang X.L., Yao X.S., et al. Icariin protects against bone loss induced by oestrogen deficiency and activates oestrogen receptor-dependent osteoblastic functions in UMR 106 cells. Br J Pharmacol 2010, 159:939-949.
15. Nan H., Ma M.H., Nan S.S., Xu L.L. Antiosteoporotic activity of icariin in ovariectomized rats. Phytomedicine 2009, 16:320-326.
16. Zheng D., Peng S., Yang S.H., Shao Z.W., Yang C., Feng Y., et al. The beneficial effect of Icariin on bone is diminished in osteoprotegerin-deficient mice. Bone 2012, 51:85-92.
17. Feng R., Feng L., Yuan Z., Wang D., Wang F., Tan B., et al. Icariin protects against glucocorticoid-induced osteoporosis in vitro and prevents glucocorticoid-induced osteocyte apoptosis in vivo. Cell Biochem Biophys 2013, 67:189-197.
18. Kapoor S. Icariin and its emerging role in the treatment of osteoporosis. Chin Med J (Engl) 2013, 126:400.
19. Wang Z.Q., Lou Y.J. Proliferation-stimulating effects of icaritin and desmethylicaritin in MCF-7 cells. Eur J Pharmacol 2004, 504:147-153.
20. Zhao J., Ohba S., Shinkai M., Chung U.I., Nagamune T. Icariin induces osteogenic differentiation in vitro in a BMP- and Runx2-dependent manner. Biochem Biophys Res Commun 2008, 369:444-448.
21. Hsieh T.P., Sheu S.Y., Sun J.S., Chen M.H., Liu M.H. Icariin isolated from Epimedium pubescens regulates osteoblasts anabolism through BMP-2, SMAD4, and Cbfa1 expression. Phytomedicine 2010, 17:414-423.
22. Pan W., Quarles L.D., Song L.H., Yu Y.H., Jiao C., Tang H.B., et al. Genistein stimulates the osteoblastic differentiation via NO/cGMP in bone marrow culture. J Cell Biochem 2005, 94:307-316.
23. Wimalawansa S.J. Nitric oxide: novel therapy for osteoporosis. Expert Opin Pharmacother 2008, 9:3025-3044.
24. Wimalawansa S.J. Nitric oxide and bone. Ann N Y Acad Sci 2010, 1192:391-403.
25. Orciani M., Trubiani O., Vignini A., Mattioli-Belmonte M., Di Primio R., Salvolini E. Nitric oxide production during the osteogenic differentiation of human periodontal ligament mesenchymal stem cells. Acta Histochem 2009, 111:15-24.
26. Liu W.J., Xin Z.C., Xin H., Yuan Y.M., Tian L., Guo Y.L. Effects of icariin on erectile function and expression of nitric oxide synthase isoforms in castrated rats. Asian J Androl 2005, 7:381-388.
27. Liu T., Xin H., Li W.R., Zhou F., Li G.Y., Gong Y.Q., et al. Effects of icariin on improving erectile function in streptozotocin-induced diabetic rats. J Sex Med 2011, 8:2761-2772.
28. Chung B.H., Kim J.D., Kim C.K., Kim J.H., Won M.H., Lee H.S., et al. Icariin stimulates angiogenesis by activating the MEK/ERK- and PI3K/Akt/eNOS-dependent signal pathways in human endothelial cells. Biochem Biophys Res Commun 2008, 376:404-408.
29. Gutiérrez S., Petiti J.P., Sosa L.V., Fozzatti L., De Paul A.L., Masini-Repiso A.M., et al. 17β-oestradiol acts as a negative modulator of insulin-induced lactotroph cell proliferation through oestrogen receptor alpha, via nitric oxide/guanylyl cyclase/cGMP. Cell Prolif 2010, 43:505-514.
30. Shao Z., Li J., Zhao Z., Gao C., Sun Z., Liu X. Effects of tetramethylpyrazine on nitric oxide/cGMP signaling after cerebral vasospasm in rabbits. Brain Res 2010, 1361:67-75.
31. Ota K.T., Monsey M.S., Wu M.S., Schafe G.E. Synaptic plasticity and NO-cGMP-PKG signaling regulate pre- and postsynaptic alterations at rat lateral amygdala synapses following fear conditioning. PLoS One 2010, 5:11236-11248.
32. Duan X.H., Xu C.Q., Huang J.H., Zhou W.J., Sun B. Icariin delays homocysteine- induced endothelial cellular senescence involving activation of the PI3K/AKT-eNOS signaling pathway. Pharm Biol 2013, 51:433-440.
33. Liang J., Slingerland J.M. Multiple roles of the PI3K/PKB (Akt) pathway in cell cycle progression. Cell Cycle 2003, 2:339-345.
34. Osaki M., Oshimura M., Ito H. PI3K-Akt pathway: its functions and alterations in human cancer. Apoptosis 2004, 9:667-676.
35. Motti M.L., Califano D., Troncone G., De Marco C., Migliaccio I., Palmieri E., et al. Complex regulation of the cyclin-dependent kinase inhibitor p27kip1 in thyroid cancer cells by the PI3K/AKT pathway: regulation of p27kip1 expression and localization. Am J Pathol 2005, 166:737-749.
36. Manning B.D., Cantley L.C. AKT/PKB signaling: navigating downstream. Cell 2007, 129:1261-1274.
37. Cantley L.C. The phosphoinositide 3-kinase pathway. Science 2002, 296:1655-1657.
38. Dimmeler S., Fleming I., Fisslthaler B., Hermann C., Busse R., Zeiher A.M. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature 1999, 399:601-605.
39. Rokutanda S., Fujita T., Kanatani N., Yoshida C.A., Komori H., Liu W., et al. Akt regulates skeletal development through GSK3, mTOR, and FoxOs. Dev Biol 2009, 328:78-93.
40. Li C.J., Chang J.K., Chou C.H., Wang G.J., Ho M.L. The PI3K/Akt/FOXO3a/p27 Kip1 signaling contributes to anti-inflammatory drug-suppressed proliferation of human osteoblasts. Biochem Pharmacol 2010, 79:926-937.
41. Mukherjee A., Rotwein P. Akt promotes BMP2-mediated osteoblast differentiation and bone development. J Cell Sci 2009, 122:716-726.
42. Ming L.G., Ge B.F., Wang M.G., Chen K.M. Comparison between 8-prenylnarigenin and narigenin on their activities to promote rat bone marrow stromal cells osteogenic differentiation in vitro. Cell Prolif 2012, 45:508-515.
43. Ma H.P., Ming L.G., Ge B.F., Zhai Y.K., Song P., Xian C.J., et al. Icarrin is more potent than genistein in promoting osteoblast differentiation and mineralization in vitro. J Cell Biochem 2011, 112:916-923.
44. Zhang Y.W., Morita I., Zhang L., Shao G., Yao X.S., Murota S. Screening of anti-hypoxia/reoxygenation agents by an in vitro method. Part 2. Inhibition of tyrosine kinase activation prevented hypoxia/reoxygenation-induced injury in endothelial gap junctional intercellular communication. Planta Med 2000, 66:119-123.
45. Chen H.P., Liao Z.P., Huang Q.R., He M. Sodium Ferulate attenuates anoxia/reoxygenation-induced calcium overload in neonatal rat cardiomyocytes by NO/cGMP/PKG pathway. Eur J Pharmacol 2009, 603:86-92.
46. Chen K.M., Ge B.F., Ma H.P., Zheng R.L. The serum of rats administered flavonoids extract of Epimedium sagittatum but not the extract itself enhance the development of rat calvarial osteoblasts in vitro. Pharmazie 2004, 59:61-64.
47. Mukherjee A., Rotwein P. Akt promotes BMP2-mediated osteoblast differentiation and bone development. J Cell Sci 2009, 122:716-726.
48. Zhai Y.K., Ge B.F., Ma H.P., Ming L.G., Li Z.Z., Cheng G.Z., et al. Icariin promotes osteogenic differentiation of rat bone marrow stromal cells in vitro. Zhongguo Zhong Yao Za Zhi 2010, 35:3219-3222.
49. Zhai Y.K., Li Z.Z., Chen K.M., Zhang N., Cheng G.Z., Zhu R.Q. Effects of icariin on the proliferation, differentiation and maturation of rat calvarial osteoblasts in vitro. Zhong Yao Cai 2011, 34:917-922.
50. Bakker A.D., Klein-Nulend J., Tanck E., Albers G.H., Lips P., Burger E.H. Additive effects of estrogen and mechanical stress on nitric oxide and prostaglandin E2 production by bone cells from osteoporotic donors. Osteoporos Int 2005, 16:983-989.
51. Hukkanen M., Platts L.A., Lawes T., Girgis S.I., Konttinen Y.T., Goodship A.E., et al. Effect of nitric oxide donor nitroglycerin on bone mineral density in a rat model of estrogen deficiency-induced osteopenia. Bone 2003, 32:142-149.
52. Wang J., Shang F., Mei Q., Wang J., Zhang R., Wang S. NO-donating genistein prodrug alleviates bone loss in ovariectomised rats. Swiss Med Wkly 2008, 138:602-607.
53. Koizumi H., Yu J., Hashimoto R., Ouchi Y., Okabe T. Involvement of androgen receptor in nitric oxide production induced by icariin in human umbilical vein endothelial cells. FEBS Lett 2010, 584:2440-2444.
54. Saura M., Tarin C., Zaragoza C. Recent insights into the implication of nitric oxide in osteoblast differentiation and proliferation during bone development. Sci Transl Med 2010, 10:624-632.
55. Wang T.T., Sathyamoorthy N., Phang J.M. Molecular effects of genistein on estrogen receptor mediated pathways. Carcinogenesis 1996, 17:271-275.
56. Morito K., Hirose T., Kinjo J., Hirakawa T., Okawa M., Nohara T., et al. Interaction of phytoestrogens with estrogen receptors alpha and beta. Biol Pharm Bull 2001, 24:351-356.
57. Ming L.G., Chen K.M., Xian C.J. Functions and action mechanisms of flavonoids genistein and icariin in regulating bone remodeling. J Cell Physiol 2013, 228:513-521.
58. Ming L.G., Lv X., Ma X.N., Ge B.F., Zhen P., Song P., et al. The prenyl group contributes to activities of phytoestrogen 8-prenynaringenin in enhancing bone formation and inhibiting bone resorption in vitro. Endocrinology 2013, 154:1202-1214.
59. Wong S.P., Shen P., Lee L., Li J., Yong E.L. Pharmacokinetics of prenylflavonoids and correlations with the dynamics of estrogen action in sera following ingestion of a standardized Epimedium extract. J Pharm Biomed 2009, 50:216-223.